1. Home
  2. HTOO vs ICU Comparison

HTOO vs ICU Comparison

Compare HTOO & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTOO
  • ICU
  • Stock Information
  • Founded
  • HTOO 2020
  • ICU 2018
  • Country
  • HTOO Ireland
  • ICU United States
  • Employees
  • HTOO N/A
  • ICU N/A
  • Industry
  • HTOO Natural Gas Distribution
  • ICU Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTOO Utilities
  • ICU Health Care
  • Exchange
  • HTOO Nasdaq
  • ICU Nasdaq
  • Market Cap
  • HTOO 12.3M
  • ICU 10.3M
  • IPO Year
  • HTOO N/A
  • ICU N/A
  • Fundamental
  • Price
  • HTOO $0.38
  • ICU $2.21
  • Analyst Decision
  • HTOO Strong Buy
  • ICU
  • Analyst Count
  • HTOO 1
  • ICU 0
  • Target Price
  • HTOO $3.50
  • ICU N/A
  • AVG Volume (30 Days)
  • HTOO 501.4K
  • ICU 24.8K
  • Earning Date
  • HTOO 12-02-2024
  • ICU 11-13-2024
  • Dividend Yield
  • HTOO N/A
  • ICU N/A
  • EPS Growth
  • HTOO N/A
  • ICU N/A
  • EPS
  • HTOO N/A
  • ICU N/A
  • Revenue
  • HTOO $4,580,524.00
  • ICU N/A
  • Revenue This Year
  • HTOO $440.97
  • ICU N/A
  • Revenue Next Year
  • HTOO $214.20
  • ICU $344.44
  • P/E Ratio
  • HTOO N/A
  • ICU N/A
  • Revenue Growth
  • HTOO N/A
  • ICU N/A
  • 52 Week Low
  • HTOO $0.32
  • ICU $1.88
  • 52 Week High
  • HTOO $4.65
  • ICU $42.93
  • Technical
  • Relative Strength Index (RSI)
  • HTOO 39.02
  • ICU 21.22
  • Support Level
  • HTOO $0.32
  • ICU $1.88
  • Resistance Level
  • HTOO $0.81
  • ICU $2.81
  • Average True Range (ATR)
  • HTOO 0.10
  • ICU 0.29
  • MACD
  • HTOO -0.02
  • ICU -0.05
  • Stochastic Oscillator
  • HTOO 18.37
  • ICU 10.92

About HTOO Fusion Fuel Green PLC

Fusion Fuel Green PLC is a company that has developed a Green Hydrogen production technology. It is focused on generating cost-effective and competitively priced Green Hydrogen.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: